During the ATHENA clinical trial, investigators evaluated a CAR-T cell therapeutic agent targeting the GPC3 antigen (AZD5851) in patients with advanced or recurrent hepatocellular carcinoma [77]. This evidence concerns the gene GPC3 and hepatocellular carcinoma.